Orion Biotechnology is discovering and developing G Protein-Coupled Receptor (GPCR) targeted therapeutics for the treatment of cancer and other serious diseases
Orion’s novel drug modality involves precision engineering ligands of small protein GPCRs, providing an enhanced solution to targeting previously-undrugged GPCRs. This approach is supported by one of the fastest drug discovery platforms in the industry and represents a large opportunity to discover and develop a new generation of GPCR-targeted medicines
CCR5 Inhibitor Program
Orion’s lead compound, OB-002, is a GPCR analog of CCL5 with best-in-classpotency and a proven mechanism of action shown to have broad applicability across a range of serious diseases, including Cancer, Infectious Disease and Neuroinflammatory disorders.
“Leveraging our novel discovery approach to generate new therapeutics rapidly and cost-effectively, Orion Biotechnology is positioned to play a prominent role in developing the next generation of GPCR-targeted drugs”
Dr. Oliver Hartley
“I am delighted with how efficiently we have accelerated the development of molecules in our pipeline, and I look forward to the continued expansion.”
Dr. Ian McGowan MD, Phd, FRCP
“The development of novel therapies is critical to address serious diseases for patients – I am delighted that Orion Biotechnology is pioneering this next frontier.”
Orion’s VP Drug Discovery, Dr. Oliver Hartley, will be presenting at PEGS Europe on November 16th. Join Dr. Hartley in Lisbon to learn how Orion is targeting small protein GPCRs
Ottawa, Canada, July 18, 2023 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs),
Ottawa, Canada, Feb. 16, 2023 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs),